Campaign against respiratory syncytial virus (RSV) in newborns ends

Campaign against respiratory syncytial virus (RSV) in newborns endsArchive

Ends today, Monday, February 5th immunization campaign against respiratory syncytia virusl (VRS) for newborns in Navarre. In this first campaign, which began on October 1 last year and ends today, A total of 1,307 boys and girls were vaccinated (as of January 29).

1069 newborns and 238 at risk.

Department of Health calculations, which were presented on February 1 to the Vaccine Commission, tentatively estimate that this first campaign achieved 91% coverage and 88% effectiveness. Since October last year, there have been 66 hospitalizations of children due to respiratory syncytial virus.

Vaccine Commission

After reviewing the epidemiological situation regarding RSV, the Vaccine Commission decided that the neonatal immunization campaign should end and continue in February and March for the pediatric population at high risk of serious RSV disease. This group includes premature infants less than 35 weeks, patients with congenital heart defects with significant hemodynamic impairment, cyanotic or non-cyanotic, bronchopulmonary dysplasia, severe immunosuppression, inborn errors of metabolism, neuromuscular and severe pulmonary diseases, genetic syndromes with associated respiratory diseases. problems, Down syndrome, cystic fibrosis and those in palliative care.